US cardiac device market to hit $4 billion by the year 2002:
This article was originally published in Clinica
The US market for implantable cardiac devices is forecast to rise from $1,700 million in 1995 to over $4,000 million by 2002. Increasing demand, combined with the development of smaller, more user-friendly and less invasive devices, are fuelling market growth, says a recent Frost & Sullivan report. Companies which can demonstrate the cost-effectiveness of their products can expect success in the current economic climate, Frost & Sullivan believes.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.